SLP — Simulations Plus, Inc.

Is SLP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Overbought As of October 3, 2026

Simulations Plus, Inc. (SLP) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Health Information Services) last closed at $18.50. The rating moved from Neutral to Overbought on September 28, 2026.

See all overbought Healthcare stocks →

AI analysis

Simulations Plus, Inc. (SLP) is a focused provider of drug‑development modeling and simulation software and related services that benefits from recurring licensing economics and growing industry adoption of in silico techniques. The firm's technical positioning in PK/PD and ADME/Tox modeling aligns with demand from late‑stage biologics and combination therapy programs, supporting steady revenue visibility and margin upside. Near‑term market risk‑off conditions and limited company‑specific disclosure create volatility and information risk; key drivers to monitor are large client renewals, new enterprise wins, and growth in subscription and services revenue. Primary downside scenarios involve meaningful R&D budget cuts, loss of major customers, or intensified competitive pricing pressure. Overall outlook: modest organic growth with upside if adoption accelerates and downside if macro or execution headwinds materialize.

Key factors

  • Recurring software licensing and subscription revenue provides predictable cash flow and margin leverage
  • Niche market position in PK/PD, ADME/Tox and regulatory-focused simulation tools with entrenched technical value for biopharma clients
  • Secular tailwinds: rising use of in silico modeling to shorten development timelines and lower trial cost, especially for complex late-stage biologics and combination therapies
  • Lower direct exposure to Medicare drug‑price negotiation dynamics compared with drug manufacturers; demand is tied to R&D activity rather than drug pricing
  • Potential catalysts include large client license renewals, new platform/adoption wins with major pharma, and expansion of consulting/CRO engagements
  • Limited company-specific public data in the provided inputs increases reliance on business model and sector dynamics

Risks

  • Client R&D budget reductions or project deferrals during prolonged market risk-off periods that reduce license renewals and services demand
  • Concentration risk if revenue depends on a small number of large customers
  • Competitive pressure from larger modeling/simulation vendors or CROs that could compress pricing or win rates
  • Small-cap liquidity and execution risk—missed product delivery, slower sales execution, or unsuccessful M&A integration could harm growth
  • Indirect exposure to broader pharmaceutical policy and payer dynamics that could change sponsor priorities
  • Absent recent EDGAR/social data in the brief increases short-term information risk and potential for surprise

See today's live rating, score and targets

Members see the live hourly rating for SLP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.